Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim in Active Crohn's Disease
NCT00206700Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2003
- Primary completion
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in Crohn's disease, sponsored by Sanofi. Primary endpoint: Safety profile of long-term, repeated cycles of sargramostim. Started Feb 2003; status: terminated.
02
Drugs
sargramostim
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00206700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206700.